The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 09, 2022

Filed:

Aug. 20, 2019
Applicant:

Bessor Pharma, Llc, Framingham, MA (US);

Inventors:

Barry A. Berkowitz, Framingham, MA (US);

Anthony G. Barrett, Rio de Janeiro, BR;

Daniel Elliott, Basel, CH;

Assignee:

Bessor Pharma, LLC, Framingham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 311/78 (2006.01); C07C 37/50 (2006.01); C07C 39/23 (2006.01); C07D 319/08 (2006.01); C07D 493/04 (2006.01); A61K 31/05 (2006.01); A61K 31/352 (2006.01);
U.S. Cl.
CPC ...
C07D 311/78 (2013.01); A61K 31/05 (2013.01); A61K 31/352 (2013.01); C07C 37/50 (2013.01); C07C 39/23 (2013.01); C07D 319/08 (2013.01); C07D 493/04 (2013.01); C07C 2601/16 (2017.05);
Abstract

A process for the preparation of substantially pure diverse known and novel cannabinoids 1 and 2, which include Δ-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), cannabidiol (11), cannabidivarin (12) and other naturally occurring tetracyclic and tricyclic cannabinoids and other synthetic tetracyclic and tricyclic analogues, via intermediates 3, 6, 4 and 5, using a cascade sequence of allylic rearrangement, aromatization and, for the tetracyclic cannabinoids, further highly stereoselective and regioselective cyclization. These synthesized cannabinoids can more easily be obtained at high purity levels than cannabinoids isolated or synthesized via known methods. The cannabinoids 2, including Δ-tetrahydrocannabinol (7), tetrahydrocannabivarin (9), are obtained containing very low levels of isomeric cannabinoids such as the undesirable Δ8-tetrahydrocannabinol. The known and novel analogues with variation in aromatic ring substituents, whilst easily synthesized with the new methodology, would be much more difficult to make from any of the components oforoil.


Find Patent Forward Citations

Loading…